

AMENDMENTS

IN THE CLAIMS

Claims 1-66, 105-112, and 121-122 were previously canceled.

Claims 67-104, 113-120 and 123-154 are pending in this Application.

Claims 145 and 148 were previously presented.


Claims 68, 70, 72, 74, 75, 78, 80, 85, 93, 100-104, 115, 123-5, 151, 153, and 154 are currently canceled.

Claims 67, 69, 71, 73, 76, 77, 79, 81-84, 86-92, 94-99, 113, 114, 116-120, 137-144, 146, 147, 149, 150, and 152 are currently amended.

Claims 126-136 are provisionally withdrawn and are subject to rejoinder, in part.

Claim 155 is new.

67. **(currently amended)** A compound of Formula I,



or a single ~~geometric isomer~~, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt ~~or hydrate~~ thereof, wherein,

R¹ is ~~methyl~~C₁-C₃-alkyl optionally substituted with ~~between one and three~~ R⁵⁰ substituents;

R² is selected from halogen, trihalomethyl, -CN, -NH₂, -NO₂, -OR³, -N(R³)R⁴, -S(O)₀₋₂R⁴, -SO₂N(R³)R⁴, -CO₂R³, -C(=O)N(R³)R⁴, -N(R³)SO₂R⁴, -N(R³)C(=O)R³, -N(R³)CO₂R⁴, -C(=O)R³, lower alkyl, lower alkenyl, and lower alkynyl;

R³ is -H or R⁴;

R⁴ is selected from lower alkyl; lower alkyl substituted with one, two, or three halogen; aryl; aryl substituted with one, two, or three halogen; unsubstituted lower

arylalkyl;₂ heterocyclyl;₂ and lower heterocyclylalkyl ~~optionally substituted with one alkyl;~~ or

R³ and R⁴, when taken together with a common nitrogen to which they are attached, form a five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P where the five- to seven-membered heterocyclyl is optionally substituted by one, two, or three alkyl;

q is 0, 1, 2, 3, 4, or 5;

Z is ~~selected from -OCH₂-, -O-, -S(O)₀₋₂-, -N(R⁵)CH₂-, and -NR⁵-;~~


R⁵ is ~~-H or lower alkyl;~~

R⁵⁰ is ~~H, halo, trihalomethyl, -OR³-, -N(R³)R⁴-, -S(O)₀₋₂R⁴-, -SO₂N(R³)R⁴-, -CO₂R³-, -C(=O)N(R³)R⁴-, -C(=NR²⁵)N(R³)R⁴-, -C(=NR²⁵)R⁴-, -N(R³)SO₂R⁴-, -N(R³)C(O)R³-, -NCO₂R³-, -C(=O)R³-, alkoxy, lower alkyl, aryl, unsubstituted lower arylalkyl, heterocyclyl, and lower heterocyclylalkyl optionally substituted with one alkyl; or two of R⁵⁰, when taken together on the same carbon are oxo; or~~

~~two of R⁵⁰, when taken together with a common carbon to which they are attached, form a three- to seven-membered spirocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P;~~

R²⁵ is ~~selected from -H-, -CN-, -NO₂-, -OR³-, -S(O)₀₋₂R⁴-, -CO₂R³-, lower alkyl, lower alkenyl, and lower alkynyl;~~

M¹-M²-M³-M⁴- together are according to formula II:



II

wherein X¹, X², and optionally X³, represent the atoms of a saturated bridged ring system, said saturated bridged ring system containing up to three annular heteroatoms represented by any of X¹, X², and X³; wherein, each X¹ is independently selected from -C(R⁶)R⁷-, -O-, -S(O)₀₋₂-, and -NR⁸-; each X² is independently a bridgehead methine optionally substituted with R⁶, or a bridgehead nitrogen;

each X^3 is independently selected from $-C(R^6)R^7-$, $-O-$, $-S(O)_{0-2}-$, and $-NR^8-$;
provided, for X^1 , X^2 , and X^3 , there are no nitrogen-nitrogen annular bonds nor
geminal di-nitrogen substitutions;

E is selected from $-NR^9-$, $-O-$, and absent;

Y is either: $-CH_2-$ provided that Y is not directly attached to

a C_{1-3} alkylene linker, between the oxygen at the 7 position of the
quinazoline ring system of I and either E, or when E is absent, any
ring atom of the saturated bridged ring system except X^2 , when X^2
is a bridgehead nitrogen; provided there are at least two carbon
atoms between the oxygen at the 7 position of the quinazoline ring
system of I and either E, or when E is absent, any heteroatom
represented by X^1 , X^2 or X^3 ; or

Y is absent, when Y is absent, E is also absent; said saturated bridged ring
system is directly attached to the oxygen at the 7 position of the
quinazoline ring system of I via a carbon atom of said saturated
bridged ring system;

m and p are each independently 1, 2, 3, or 4;

n is 0, 1, or 2, when n is zero, then there is a direct single bond between the two
bridgehead X^2 's;

R^6 and R^7 are each independently selected from $-H$, halogen, trihalomethyl,
 $-CN$, $-NH_2$, $-NO_2$, $-OR^3$, $-N(R^3)R^4$, $-S(O)_{0-2}R^4$, $-SO_2N(R^3)R^4$, $-CO_2R^3$,
 $-C(O)N(R^3)R^4$, $-N(R^3)SO_2R^4$, $-N(R^3)C(O)R^3$, $-NCO_2R^3$, $-C(O)R^3$, lower
alkyl, aryl, unsubstituted lower arylalkyl, heterocyclyl optionally
substituted with one alkyl, and lower heterocyclylalkyl optionally
substituted with one alkyl; or

R^6 and R^7 , when taken together are oxo; or

R^6 and R^7 , when taken together with a common carbon to which they are attached,
form a three- to seven-membered spirocyclyl optionally containing at least

one additional heteroatom selected from N, O, S, and P and wherein the spirocyclic ring is optionally substituted with one or two alkyl; and R^8 is selected from R^3 , $-\text{SO}_2\text{N}(R^3)R^4$, $-\text{CO}_2R^3$, $-\text{C}(\text{O})\text{N}(R^3)R^4$, $-\text{SO}_2R^4$, and $-\text{C}(\text{O})R^3$;

~~R^9 is H or lower alkyl;~~

with the proviso that when Y is a C_{1-3} alkylene linker, E is absent, Z is $-\text{NH}-$ or $-\text{N}(\text{CH}_3)-$, R^1 is a C_{1-3} alkyl, R^2 is $-\text{H}$ or halogen, $n = 0$, and the atoms X^1 of one bridge of the saturated bridged ring system, when combined with both bridgehead atoms, X^2 , of the saturated bridged ring system, represent:

either a pyrrolidine ring or a piperidine ring, and any atom, X^1 or X^2 , of either of said pyrrolidine ring or said piperidine ring is attached to Y; then the other bridge of said saturated bridged ring system cannot be any one of $-\text{OC}(\text{O})\text{CH}_2-$, $-\text{CH}_2\text{OC}(\text{O})-$, $-\text{OC}(\text{O})\text{CH}_2\text{CH}_2-$, $-\text{CH}_2\text{OC}(\text{O})\text{CH}_2-$, $-\text{CH}_2\text{CH}_2\text{OC}(\text{O})-$, $-\text{OC}(\text{O})\text{CH}_2\text{NH}-$, $-\text{OC}(\text{O})\text{CH}_2\text{N}(\text{C}_{1-4}\text{alkyl})-$, and $-\text{OC}(\text{O})\text{CH}_2\text{O}-$; and

either a piperazine ring or a 4- $(\text{C}_{1-4}\text{ alkyl})$ -piperazine ring, and any atom, X^1 or X^2 , of either of said piperazine ring or said 4- $(\text{C}_{1-4}\text{ alkyl})$ -piperazine ring is attached to Y; then the other bridge of said saturated bridged ring system, only when attached via the 2- and the 3-position of either of said piperazine ring or said 4- $(\text{C}_{1-4}\text{ alkyl})$ -piperazine ring, cannot be one of $-\text{CH}_2\text{OC}(\text{O})\text{CH}_2-$, $-\text{CH}_2\text{CH}_2\text{OC}(\text{O})-$, and either of the two aforementioned bridges ~~cannot be optionally~~ substituted by one or two C_{1-2} alkyl groups;[[or]] and

~~a piperazine ring, and any atom, X^1 or X^2 , of said piperazine ring is attached to Y; then the other bridge of said saturated bridged ring system, only when attached via the 3- and the 4 position of said piperazine ring, cannot be one of $-\text{C}(\text{O})\text{OCH}_2\text{CH}_2-$ or $-\text{CH}_2\text{OC}(\text{O})\text{CH}_2-$ (and only when either of $-\text{C}(\text{O})\text{OCH}_2\text{CH}_2-$ or $-\text{CH}_2\text{OC}(\text{O})\text{CH}_2-$ is attached to the 3 position of said piperazine ring via their left hand end as depicted above), and either~~

~~of the two aforementioned bridges cannot be optionally substituted by one or two C₁₋₂ alkyl groups; and~~
a piperazine ring, and any atom, X¹ or X², of said piperazine ring is attached to Y; then the other bridge of said saturated bridged ring system, only when attached via the 3- and the 4-position of said piperazine ring, cannot be -C(O)OCH₂CH₂-, -CH₂OC(O)CH₂-, -C(O)OCH₂CH₂- substituted with one or two C₁₋₂ alkyl groups, or -CH₂OC(O)CH₂- substituted with one or two C₁₋₂ alkyl groups (but only when the four above mentioned bridges are attached to the 3-position of said piperazine ring via their left-hand end as depicted above); and
a 2-oxomorpholine ring, said 2-oxomorpholine ring attached to Y via its 4-position; then the other bridge of said saturated bridged ring system, only when attached via the 5- and the 6-position of said 2-oxomorpholine ring, cannot be one of -(CH₂)_g-, -CH₂WCH₂-, -CH₂WCH₂CH₂-, and -CH₂CH₂WCH₂-, wherein W is -O-, -S(O)₀₋₂-, -NH-, or -N(C₁₋₄ alkyl)- and wherein g is 2, 3, or 4.

68. (canceled)

69. (currently amended) The compound according to claim ~~67~~⁶⁸, wherein R² is selected from halogen, trihalomethyl, -CN, -NO₂, -OR³, and lower alkyl; or a single ~~geometric isomer~~, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt ~~or hydrate~~ thereof.

70. (canceled)

71. (currently amended) The compound according to claim ~~69~~⁷⁰, wherein the saturated bridged ring system has a geometry selected from the group consisting of [4.4.0], [4.3.0], [4.2.0], [4.1.0], [3.3.0], [3.2.0], [3.1.0], [3.3.3], [3.3.2], [3.3.1], [3.2.2], [3.2.1], [2.2.2], and [2.2.1]; or a single ~~geometric isomer~~, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt ~~or hydrate~~ thereof.

72. (canceled)

73. **(currently amended)** The compound according to claim ~~7172~~, wherein q is 1, 2, or 3; or a single ~~geometric isomer~~, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt ~~or hydrate~~ thereof.

74. **(canceled)**


75. **(canceled)**

76. **(currently amended)** The compound according to claim ~~7375~~, wherein the saturated bridged ring system has a geometry selected from the group consisting of [4.4.0], [4.3.0], [4.2.0], [4.1.0], [3.3.0], [3.2.0], and [3.1.0]; or a single ~~geometric isomer~~, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt ~~or hydrate~~ thereof.

77. **(currently amended)** The compound according to claim 76, wherein said saturated bridged ring system contains one or two annular nitrogens, said one or two annular nitrogens are selected from $-NR^8$ -, when X^1 , and a bridgehead nitrogen, when X^2 ; or a single ~~geometric isomer~~, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt ~~or hydrate~~ thereof.

78. **(canceled)**

79. **(currently amended)** The compound according to claim ~~7778~~, wherein said saturated bridged ring system is according to formula **III**;



III


wherein A is selected from $-O-$, $-S(O)_{0-2}-$, $-NR^8$ -, and absent; and e is 0 or 1; or a single ~~geometric isomer~~, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt ~~or hydrate~~ thereof.

80. **(canceled)**

81. **(currently amended)** The compound according to claim ~~7980~~, wherein A is selected from $-NR^8$ -, wherein R^8 is selected from $-H$, lower alkyl, $-CO_2R^3$,

$-\text{C}(\text{O})\text{N}(\text{R}^3)\text{R}^4$, $-\text{SO}_2\text{R}^4$, and $-\text{C}(\text{O})\text{R}^3$; $-\text{O}-$; and absent; or a single ~~geometric isomer~~, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt ~~or hydrate~~ thereof.


82. **(currently amended)** The compound according to claim 81, wherein




R^{2b} , and R^{2c} are each independently selected from F, Cl, and Br; or a single ~~geometric isomer~~, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt ~~or hydrate~~ thereof.

83. **(currently amended)** The compound according to claim 82, wherein R^{2a} is F, R^{2b} is Cl, and R^{2c} is either Cl or Br; or a single ~~geometric isomer~~, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt ~~or hydrate~~ thereof.

84. **(currently amended)** The compound according to claim 77, wherein said saturated bridged ring system is according to either formula V or formula VI;



V




VI

wherein R^8 is selected from $-\text{H}$, lower alkyl, $-\text{CO}_2\text{R}^3$, $-\text{C}(\text{O})\text{N}(\text{R}^3)\text{R}^4$, $-\text{SO}_2\text{R}^4$, and $-\text{C}(\text{O})\text{R}^3$; or a single ~~geometric isomer~~, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt ~~or hydrate~~ thereof.

85. **(canceled)**

86. **(currently amended)** The compound according to claim ~~84~~85, wherein




R^{2b}, and R^{2c} are each independently selected from F, Cl, and Br; or a single ~~geometric isomer~~, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt ~~or hydrate~~ thereof.

87. (currently amended) The compound according to claim 86, wherein R^{2a} is F, R^{2b} is Cl, and R^{2c} is either Cl or Br; or a single ~~geometric isomer~~, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt ~~or hydrate~~ thereof.

88. (currently amended) The compound according to claim 87, wherein R⁸ is methyl or ethyl; or a single ~~geometric isomer~~, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt ~~or hydrate~~ thereof.

89. (currently amended) The compound according to claim ~~777~~**8**, wherein said



saturated bridged ring system is according to formula **VII**;

VII

wherein A is selected from -O-, -S(O)₀₋₂-, -NR⁸-, -CR⁶R⁷-, and absent; or a single ~~geometric isomer~~, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt ~~or hydrate~~ thereof.

90. (currently amended) The compound according to claim 89, wherein R³ is selected from -H and alkyl; or a single ~~geometric isomer~~, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt ~~or hydrate~~ thereof.


91. **(currently amended)** The compound according to claim 90 wherein A is either $-C(R^6)R^7$ or absent; or a single ~~geometric isomer~~, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt ~~or hydrate~~ thereof.

92. **(currently amended)** The compound according to claim 91, wherein A is either $-CH_2-$ or absent; or a single ~~geometric isomer~~, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt ~~or hydrate~~ thereof.

93. **(canceled)**

94. **(currently amended)** The compound according to claim ~~92~~93, wherein q is 3; or a single ~~geometric isomer~~, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt ~~or hydrate~~ thereof.

95. **(currently amended)** The compound according to claim 94, wherein




R^{2b} , and R^{2c} are each independently selected from F, Cl, and Br; or a single ~~geometric isomer~~, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt ~~or hydrate~~ thereof.

96. **(currently amended)** The compound according to claim 95, wherein R^{2a} is F, R^{2b} is Cl, and R^{2c} is either Cl or Br; or a single ~~geometric isomer~~, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt ~~or hydrate~~ thereof.


97. **(currently amended)** The compound according to claim ~~73~~75, wherein the saturated bridged ring system has a geometry selected from the group consisting of [3.3.1], [3.2.1], and [2.2.1]; or a single ~~geometric isomer~~, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt ~~or hydrate~~ thereof.

98. **(currently amended)** The compound according to claim 97, wherein said saturated bridged ring system contains one or two annular nitrogens, said one or two annular nitrogens are selected from $\text{-NR}^8\text{-}$, when X^1 , and a bridgehead nitrogen, when X^2 ; or a single ~~geometric isomer~~, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt ~~or hydrate~~ thereof.

99. **(currently amended)** The compound according to claim 98, wherein said saturated bridged ring system is according to formula **VIII** or formula **IX**;



VIII




IX

wherein R^8 is selected from -H , lower alkyl, $\text{-CO}_2\text{R}^3$, $\text{-C(O)N(R}^3\text{)R}^4$, $\text{-SO}_2\text{R}^4$, and -C(O)R^3 ; and R^{26} is C_{1-3} alkyl; or a single ~~geometric isomer~~, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt ~~or hydrate~~ thereof.

Claims 100-104 (canceled)

Claims 105-112 (previously canceled)

113. **(currently amended)** A compound of Formula Ia,



Ia

or a single ~~geometric isomer~~, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt ~~or hydrate~~ thereof, wherein, q is 1, 2, or 3;

R^2 is selected from halogen, trihalomethyl, -CN , -NO_2 , -OR^3 , lower alkyl, and piperazinyl substituted with methyl;

Y is either:

~~-CH₂- or -CH₂CH₂- provided there are at least two carbon atoms between the oxygen at the 7-position of the quinazoline ring system of Ia and E when E is -NR⁹- or -O-; or~~

~~Y is absent; and when Y is absent, E is also absent;~~

~~E is selected from -NR⁹-, -O-, and absent;~~

~~R³ is -H or R⁴;~~

~~R⁴ is selected from lower alkyl; lower alkyl substituted with one, two, or three halogen; aryl; aryl substituted with one, two, or three halogen; unsubstituted lower arylalkyl; heterocyclyl; and lower heterocyclalkyl optionally substituted with one alkyl; or~~

~~R³ and R⁴, when taken together with a common nitrogen to which they are attached, form a five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P where the five- to seven-membered heterocyclyl is optionally substituted by one, two, or three alkyl;~~

~~R⁹ is -H or lower alkyl;~~

~~R¹⁰ is selected from -H, alkyl, and -OR¹³; and R¹¹ and R¹² are each independently selected from -H, -CF₃, -F, -N(R³)R⁴, -N(C=O)R³, -N(R³)SO₂R³, -S(O)₀₋₂R¹³, -OR¹³, -OS(O)₂alkyl, -NH₂, and alkyl substituted with alkoxy; or~~

~~R¹⁰ is selected from -H, and -OR¹³; and R¹¹ and R¹², when taken together, are oxo, exo-alkenyl, or when taken together with the carbon to which they are attached, form a three- to seven-membered spirocyclyl; and~~

~~R¹³ is selected from -H;₁ -C(=O)R⁴₁; lower alkynyl₁; unsubstituted lower arylalkynyl₁; lower heterocyclalkynyl optionally substituted with one alkyl₁; lower alkenyl₁; unsubstituted lower arylalkenyl₁; lower heterocyclalkenyl optionally substituted with one alkyl₁; lower alkyl₁; lower alkyl substituted with one, two, or three halogen₁; unsubstituted lower arylalkyl₁; aryl₁; lower heterocyclalkyl optionally substituted with one alkyl₁; and heterocyclyl; or~~

~~two R¹³'s, when taken together, form 1) a corresponding spirocyclic ketal from R¹¹, R¹² and the carbon to which they are attached, when R¹¹ and R¹² are both -OR¹³, or 2)~~

a corresponding cyclic ketal from R^{10} and one of R^{11} and R^{12} , and the corresponding carbons to which they are attached, when R^{10} is $-OR^{13}$, and at least one of R^{11} and R^{12} is also $-OR^{13}$, and which spirocyclic and cyclic ketal are ~~independently~~ optionally substituted with one or two alkyl.

114. **(currently amended)** The Compound of Claim 113 wherein

q is 1, 2, or 3;

R^2 is selected from halogen, trihalomethyl, $-CN$, $-NO_2$, $-OR^3$, and lower alkyl;

Y is ~~either:~~

~~$-CH_2-$ or $-CH_2CH_2-$ provided there are at least two carbon atoms between the oxygen at the 7-position of the quinazoline ring system of Ia and E when E is $-NR^9$ or $-O$; or~~

~~Y is absent; and when Y is absent, E is also absent;~~

~~E is selected from $-NR^9$, $-O$, and absent;~~

R^3 is $-H$ or R^4 ;

R^4 is selected from lower alkyl; lower alkyl substituted with one, two, or three halogen; aryl; aryl substituted with one, two, or three halogen; unsubstituted lower arylalkyl; heterocyclyl; and lower heterocyclylalkyl ~~optionally substituted with one alkyl; or~~

R^3 and R^4 , when taken together with a common nitrogen to which they are attached, form a five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P where the five- to seven-membered heterocyclyl is optionally substituted by one, two, or three alkyl;

~~R^9 is $-H$ or lower alkyl;~~

R^{10} is selected from $-H$, alkyl, and $-OR^{13}$; and R^{11} and R^{12} are each independently selected from $-H$, $-CF_3$, $-F$, $-N(R^3)R^4$, $-N(C=O)R^3$, $-N(R^3)SO_2R^3$, $-S(O)_{0.2}R^{13}$, and $-OR^{13}$; or

R^{10} is selected from $-H$, and $-OR^{13}$; and R^{11} and R^{12} , when taken together, are oxo, exo-alkenyl, or when taken together with the carbon to which they are attached, form a three- to seven-membered spirocyclyl; and

R^{13} is selected from $-H$; $-C(=O)R^4$; lower alkynyl; unsubstituted lower arylalkynyl; lower heterocyclalkynyl ~~optionally substituted with one alkyl~~; lower alkenyl; unsubstituted lower arylalkenyl; ~~lower heterocyclalkenyl optionally substituted with one alkyl~~; lower alkyl; lower alkyl substituted with one, two, or three halogen; unsubstituted lower arylalkyl; aryl; lower heterocyclalkyl optionally substituted with one alkyl; and heterocycl; or
two R^{13} 's, when taken together, form 1) a corresponding spirocyclic ketal from R^{11} , R^{12} and the carbon to which they are attached, when R^{11} and R^{12} are both $-OR^{13}$, or 2) a corresponding cyclic ketal from R^{10} and one of R^{11} and R^{12} , and the corresponding carbons to which they are attached, when R^{10} is $-OR^{13}$, and at least one of R^{11} and R^{12} is also $-OR^{13}$; or a single ~~geometric isomer~~, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt ~~or hydrate~~ thereof.

115. **(canceled)**

116. **(currently amended)** The compound according to claim ~~114~~115, wherein one of R^{11} and R^{12} is $-OR^{13}$, wherein R^{13} is selected from $-H$, $-C(O)R^4$, lower alkyl, and lower alkyl substituted with one, two, or three halogen; and R^{10} and the other of R^{11} and R^{12} are both $-H$; or a single ~~geometric isomer~~, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt ~~or hydrate~~ thereof.

117. **(currently amended)** The compound according to claim ~~114~~115, wherein one of R^{11} and R^{12} is $-F$; and R^{10} and the other of R^{11} and R^{12} are both $-H$; or a single ~~geometric isomer~~, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt ~~or hydrate~~ thereof.

118. **(currently amended)** The compound according to claim ~~114~~115, wherein R^{13} is a ~~lower~~ alkyl group containing at least one fluorine substitution thereon; or a single ~~geometric isomer~~, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt ~~or hydrate~~ thereof.

119. **(currently amended)** The compound according to claim ~~114~~115, wherein q is 2 or 3, ~~or a single geometric isomer,~~ stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt ~~or hydrate~~ thereof.

120. **(currently amended)** The compound according to claim 119, wherein each R² is independently selected from -F, -Cl, -Br, -CF₃, -CH₃, and -OR²⁵; wherein R²⁵ is either methyl or aryl, each optionally substituted with one to three halogens; or a single ~~geometric isomer,~~ stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt ~~or hydrate~~ thereof.

Claims 121-122 (previously canceled)

Claim 123-125 (canceled)

Claims 126-136 (provisionally withdrawn, subject to rejoinder)

137. **(currently amended)** The compound of Claim ~~68~~67 selected from

<i>N</i> -(3,4-dichlorophenyl)-6-(methyloxy)-7-([(8 <i>aR</i>)-tetrahydro-1 <i>H</i> -[1,3]thiazolo[4,3- <i>c</i>][1,4]oxazin-6-ylmethyl)oxy}quinazolin-4-amine;
<i>N</i> -(3,4-dichlorophenyl)-6-(methyloxy)-7-[(tetrahydro-1 <i>H</i> -[1,3]thiazolo[4,3- <i>c</i>][1,4]oxazin-3-ylmethyl)oxy]quinazolin-4-amine
<i>N</i> -(3,4-dichloro-2-fluorophenyl)-6-(methyloxy)-7-[(octahydro-2 <i>H</i> -quinolizin-3-ylmethyl)oxy]quinazolin-4-amine;
<i>N</i> -(4-bromo-3-chlorophenyl)-7-[(3 <i>a'S</i> ,4 <i>R</i> ,6' <i>S</i> ,6 <i>a'R</i>)-2,2-dimethyltetrahydrospiro[1,3-dioxolane-4,3'-furo[3,2- <i>b</i>]furan]-6'-yl]oxy}-6-(methyloxy)quinazolin-4-amine;
1,4:3,6-dianhydro-2- <i>O</i> -[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5- <i>O</i> -(methylsulfonyl)- <i>L</i> -glucitol;
1,4:3,6-dianhydro-2- <i>O</i> -[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5- <i>O</i> -(methylsulfonyl)- <i>D</i> -glucitol;
2-amino-1,4:3,6-dianhydro-5- <i>O</i> -[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy- <i>D</i> -iditol;
2-amino-1,4:3,6-dianhydro-5- <i>O</i> -[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy- <i>L</i> -iditol;
1,4:3,6-dianhydro-2-deoxy-2-fluoro-5- <i>O</i> -(6-(methyloxy)-4-[[4-(4-methylpiperazin-1-yl)phenyl]amino]quinazolin-7-yl)- <i>D</i> -iditol;
1,4:3,6-dianhydro-2-deoxy-2-fluoro-5- <i>O</i> -(6-(methyloxy)-4-[[4-(4-methylpiperazin-1-yl)phenyl]amino]quinazolin-7-yl)- <i>L</i> -iditol;

1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-O-[4-{{[3-fluoro-4-(4-methylpiperazin-1-yl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl}] D -iditol;
1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-O-[4-{{[3-fluoro-4-(4-methylpiperazin-1-yl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl}] L -iditol;
1,4:3,6-dianhydro-2-deoxy-5-O-[4-{{[2,3-dichloro-4-(4-methylpiperazin-1-yl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl}] 2-fluoro D -iditol;
1,4:3,6-dianhydro-2-deoxy-5-O-[4-{{[2,3-dichloro-4-(4-methylpiperazin-1-yl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl}] 2-fluoro L -iditol;
1,4:3,6-dianhydro-2-deoxy-5-O-[4-{{[3,4-dichloro-2-(4-methylpiperazin-1-yl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl}] 2-fluoro D -iditol;
1,4:3,6-dianhydro-2-deoxy-5-O-[4-{{[3,4-dichloro-2-(4-methylpiperazin-1-yl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl}] 2-fluoro L -iditol; and
a single geometric isomer , stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

138. **(currently amended)** The Compound of Claim 81 selected from

<i>N</i> -(4-bromo-2,3-dichlorophenyl)-7-{{[(3 <i>R</i> ,9 <i>aS</i>)-hexahydro-1 <i>H</i> -[1,4]oxazino[3,4- <i>c</i>][1,4]oxazin-3-ylmethyl]oxy}}-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(4,5-dichloro-2-fluorophenyl)-7-{{[(3 <i>R</i> ,9 <i>aS</i>)-hexahydro-1 <i>H</i> -[1,4]oxazino[3,4- <i>c</i>][1,4]oxazin-3-ylmethyl]oxy}}-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(4-bromo-5-chloro-2-fluorophenyl)-7-{{[(3 <i>R</i> ,9 <i>aS</i>)-hexahydro-1 <i>H</i> -[1,4]oxazino[3,4- <i>c</i>][1,4]oxazin-3-ylmethyl]oxy}}-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(3-chloro-2,4-difluorophenyl)-7-{{[(3 <i>R</i> ,9 <i>aS</i>)-hexahydro-1 <i>H</i> -[1,4]oxazino[3,4- <i>c</i>][1,4]oxazin-3-ylmethyl]oxy}}-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(3,4-dichloro-2-fluorophenyl)-7-{{[(3 <i>S</i> ,9 <i>aS</i>)-hexahydro-1 <i>H</i> -[1,4]oxazino[3,4- <i>c</i>][1,4]oxazin-3-ylmethyl]oxy}}-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(4-bromo-3-chloro-2-fluorophenyl)-7-{{[(3 <i>S</i> ,9 <i>aS</i>)-hexahydro-1 <i>H</i> -[1,4]oxazino[3,4- <i>c</i>][1,4]oxazin-3-ylmethyl]oxy}}-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(3-chloro-2,4-difluorophenyl)-7-{{[(3 <i>S</i> ,9 <i>aS</i>)-hexahydro-1 <i>H</i> -[1,4]oxazino[3,4- <i>c</i>][1,4]oxazin-3-ylmethyl]oxy}}-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(3,4-dichlorophenyl)-7-[(hexahydro-1 <i>H</i> -[1,4]oxazino[3,4- <i>c</i>][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;

<i>N</i> -(4,5-dichloro-2-fluorophenyl)-7-{[(3 <i>S</i> ,9 <i>aS</i>)-hexahydro-1 <i>H</i> -[1,4]oxazino[3,4- <i>c</i>][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(4-bromo-2,3-dichlorophenyl)-7-{[(3 <i>S</i> ,9 <i>aS</i>)-hexahydro-1 <i>H</i> -[1,4]oxazino[3,4- <i>c</i>][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(4-bromo-5-chloro-2-fluorophenyl)-7-{[(3 <i>S</i> ,9 <i>aS</i>)-hexahydro-1 <i>H</i> -[1,4]oxazino[3,4- <i>c</i>][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(3,4-dichloro-2-fluorophenyl)-7-{[(3 <i>R</i> ,9 <i>aS</i>)-hexahydro-1 <i>H</i> -[1,4]oxazino[3,4- <i>c</i>][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(4-bromo-3-chloro-2-fluorophenyl)-7-{[(3 <i>R</i> ,9 <i>aS</i>)-hexahydro-1 <i>H</i> -[1,4]oxazino[3,4- <i>c</i>][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine; and
a single geometric isomer , stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

139. **(currently amended)** The Compound of Claim 81 selected from

<i>N</i> -(3,4-dichlorophenyl)-7-{[(3 <i>R</i> ,8 <i>aR</i>)-hexahydro-1 <i>H</i> -pyrrolo[2,1- <i>c</i>][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(4-bromo-5-chloro-2-fluorophenyl)-7-{[(3 <i>S</i> ,8 <i>aS</i>)-hexahydro-1 <i>H</i> -pyrrolo[2,1- <i>c</i>][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(3,4-dichlorophenyl)-7-{[(3 <i>S</i> ,8 <i>aR</i>)-hexahydro-1 <i>H</i> -pyrrolo[2,1- <i>c</i>][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(3,4-dichlorophenyl)-7-{[(3 <i>S</i> ,8 <i>aS</i>)-hexahydro-1 <i>H</i> -pyrrolo[2,1- <i>c</i>][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(3,4-dichlorophenyl)-7-{[(3 <i>R</i> ,8 <i>aS</i>)-hexahydro-1 <i>H</i> -pyrrolo[2,1- <i>c</i>][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(3,4-dichloro-2-fluorophenyl)-7-{[(3 <i>S</i> ,8 <i>aS</i>)-hexahydro-1 <i>H</i> -pyrrolo[2,1- <i>c</i>][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(4-bromo-3-chloro-2-fluorophenyl)-7-{[(3 <i>S</i> ,8 <i>aS</i>)-hexahydro-1 <i>H</i> -pyrrolo[2,1- <i>c</i>][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(3-chloro-2,4-difluorophenyl)-7-{[(3 <i>S</i> ,8 <i>aS</i>)-hexahydro-1 <i>H</i> -pyrrolo[2,1- <i>c</i>][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(4-bromo-2,3-dichlorophenyl)-7-{[(3 <i>S</i> ,8 <i>aS</i>)-hexahydro-1 <i>H</i> -pyrrolo[2,1- <i>c</i>][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;

N-(4,5-dichloro-2-fluorophenyl)-7-({[(3*S*,8*aS*)-hexahydro-1*H*-pyrrolo[2,1-*c*][1,4]oxazin-3-ylmethyl}oxy)-6-(methyloxy)quinazolin-4-amine; and

a single ~~geometric isomer~~, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt ~~or hydrate~~ thereof.

140. (**currently amended**) The Compound of Claim ~~85~~84 selected from

N-(3,4-dichloro-2-fluorophenyl)-7-({[(3*aR*,6*aS*)-2-(1-methylethyl)octahydrocyclopenta[*c*]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;

N-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3*aR*,6*aS*)-2-(1-methylethyl)octahydrocyclopenta[*c*]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;

7-({[(3*aR*,6*aS*)-2-acetyloctahydrocyclopenta[*c*]pyrrol-5-yl]methyl}oxy)-*N*-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)quinazolin-4-amine;

N-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3*aR*,6*aS*)-octahydrocyclopenta[*c*]pyrrol-5-ylmethyl]oxy} quinazolin-4-amine;

N-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3*aR*,6*aS*)-2-(methylsulfonyl)octahydrocyclopenta[*c*]pyrrol-5-yl]methyl}oxy)quinazolin-4-amine;

N-(3,4-dichloro-2-fluorophenyl)-7-({[(3*aR*,6*aS*)-2-ethyloctahydrocyclopenta[*c*]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;

N-(3,4-dichloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3*aR*,6*aS*)-2-(2-methylpropyl)octahydrocyclopenta[*c*]pyrrol-5-yl]methyl}oxy)quinazolin-4-amine;

N-(3,4-dichloro-2-fluorophenyl)-7-({[(3*aR*,6*aS*)-2-methyloctahydrocyclopenta[*c*]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;

N-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3*aR*,6*aS*)-2-methyloctahydrocyclopenta[*c*]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;

N-(3-chloro-2,4-difluorophenyl)-7-({[(3*aR*,6*aS*)-2-methyloctahydrocyclopenta[*c*]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;

N-(4,5-dichloro-2-fluorophenyl)-7-({[(3*aR*,6*aS*)-2-methyloctahydrocyclopenta[*c*]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;

N-(4-bromo-5-chloro-2-fluorophenyl)-7-({[(3*aR*,6*aS*)-2-methyloctahydrocyclopenta[*c*]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;

<i>N</i> -(4-bromo-2,3-dichlorophenyl)-7-({[(3 <i>aR</i> ,6 <i>aS</i>)-2-methyloctahydrocyclopenta[<i>c</i>]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(3,4-dichlorophenyl)-7-({[(3 <i>aR</i> ,6 <i>aS</i>)-2-methyloctahydrocyclopenta[<i>c</i>]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3 <i>aR</i> ,6 <i>aS</i>)-2-ethyloctahydrocyclopenta[<i>c</i>]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3 <i>aR</i> ,6 <i>aS</i>)-2-(2-methylpropyl)octahydrocyclopenta[<i>c</i>]pyrrol-5-yl]methyl}oxy)quinazolin-4-amine; and
a single geometric isomer , stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

141. **(currently amended)** The Compound of Claim ~~85~~84 selected from

<i>N</i> -(3-chloro-2,4-difluorophenyl)-7-({[(3 <i>aR</i> ,5 <i>s</i> ,6 <i>aS</i>)-2-methyloctahydrocyclopenta[<i>c</i>]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(3-chloro-2,4-difluorophenyl)-7-({[(3 <i>aR</i> ,5 <i>r</i> ,6 <i>aS</i>)-2-methyloctahydrocyclopenta[<i>c</i>]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(4-bromo-2,3-dichlorophenyl)-7-({[(3 <i>aR</i> ,5 <i>s</i> ,6 <i>aS</i>)-2-methyloctahydrocyclopenta[<i>c</i>]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(4-bromo-2,3-dichlorophenyl)-7-({[(3 <i>aR</i> ,5 <i>r</i> ,6 <i>aS</i>)-2-methyloctahydrocyclopenta[<i>c</i>]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(3,4-dichlorophenyl)-7-({[(3 <i>aR</i> ,5 <i>s</i> ,6 <i>aS</i>)-2-methyloctahydrocyclopenta[<i>c</i>]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(3,4-dichlorophenyl)-7-({[(3 <i>aR</i> ,5 <i>r</i> ,6 <i>aS</i>)-2-methyloctahydrocyclopenta[<i>c</i>]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine; <u>and</u>
<i>N</i> -(3,4-dichlorophenyl)-7-({[(3 <i>aR</i> ,6 <i>aS</i>)-2-methyloctahydrocyclopenta[<i>c</i>]pyrrol-5-yl]oxy)-6-(methyloxy)quinazolin-4-amine; and
a single geometric isomer , stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

142. **(currently amended)** The Compound of Claim 87 selected from

<i>N</i> -(3,4-dichloro-2-fluorophenyl)-7-({[(3 <i>aR</i> ,5 <i>r</i> ,6 <i>aS</i>)-2-(1-methylethyl)octahydrocyclopenta[<i>c</i>]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3 <i>aR</i> ,5 <i>r</i> ,6 <i>aS</i>)-2-(1-methylethyl)octahydrocyclopenta[<i>c</i>]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
7-({[(3 <i>aR</i> ,5 <i>r</i> ,6 <i>aS</i>)-2-acetyloctahydrocyclopenta[<i>c</i>]pyrrol-5-yl]methyl}oxy)- <i>N</i> -(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3 <i>aR</i> ,5 <i>r</i> ,6 <i>aS</i>)-octahydrocyclopenta[<i>c</i>]pyrrol-5-ylmethyl]oxy}quinazolin-4-amine;
ethyl (3 <i>aR</i> ,6 <i>aS</i>)-5-({[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)hexahydrocyclopenta[<i>c</i>]pyrrole-2(1 <i>H</i>)-carboxylate;
ethyl (3 <i>aR</i> ,5 <i>r</i> ,6 <i>aS</i>)-5-({[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)hexahydrocyclopenta[<i>c</i>]pyrrole-2(1 <i>H</i>)-carboxylate;
<i>N</i> -(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3 <i>aR</i> ,5 <i>r</i> ,6 <i>aS</i>)-2-(methylsulfonyl)octahydrocyclopenta[<i>c</i>]pyrrol-5-yl]methyl}oxy)quinazolin-4-amine;
<i>N</i> -(3,4-dichloro-2-fluorophenyl)-7-({[(3 <i>aR</i> ,5 <i>r</i> ,6 <i>aS</i>)-2-ethyloctahydrocyclopenta[<i>c</i>]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(3,4-dichloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3 <i>aR</i> ,5 <i>r</i> ,6 <i>aS</i>)-2-(2-methylpropyl)octahydrocyclopenta[<i>c</i>]pyrrol-5-yl]methyl}oxy)quinazolin-4-amine;
<i>N</i> -(3,4-dichloro-2-fluorophenyl)-7-({[(3 <i>aR</i> ,5 <i>s</i> ,6 <i>aS</i>)-2-methyloctahydrocyclopenta[<i>c</i>]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(3,4-dichloro-2-fluorophenyl)-7-({[(3 <i>aR</i> ,5 <i>r</i> ,6 <i>aS</i>)-2-methyloctahydrocyclopenta[<i>c</i>]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3 <i>aR</i> ,5 <i>s</i> ,6 <i>aS</i>)-2-methyloctahydrocyclopenta[<i>c</i>]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3 <i>aR</i> ,5 <i>r</i> ,6 <i>aS</i>)-2-methyloctahydrocyclopenta[<i>c</i>]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(4,5-dichloro-2-fluorophenyl)-7-({[(3 <i>aR</i> ,5 <i>s</i> ,6 <i>aS</i>)-2-methyloctahydrocyclopenta[<i>c</i>]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;

<i>N</i> -(4,5-dichloro-2-fluorophenyl)-7-({[(3 <i>aR</i> ,5 <i>r</i> ,6 <i>aS</i>)-2-methyloctahydrocyclopenta[<i>c</i>]pyrrol-5-yl)methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(4-bromo-5-chloro-2-fluorophenyl)-7-({[(3 <i>aR</i> ,5 <i>s</i> ,6 <i>aS</i>)-2-methyloctahydrocyclopenta[<i>c</i>]pyrrol-5-yl)methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(4-bromo-5-chloro-2-fluorophenyl)-7-({[(3 <i>aR</i> ,5 <i>r</i> ,6 <i>aS</i>)-2-methyloctahydrocyclopenta[<i>c</i>]pyrrol-5-yl)methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3 <i>aR</i> ,5 <i>r</i> ,6 <i>aS</i>)-2-methyloctahydrocyclopenta[<i>c</i>]pyrrol-5-yl)methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3 <i>aR</i> ,5 <i>r</i> ,6 <i>aS</i>)-2-(2-methylpropyl)octahydrocyclopenta[<i>c</i>]pyrrol-5-yl)methyl}oxy)quinazolin-4-amine;
1,1-dimethylethyl (3 <i>aR</i> ,6 <i>aS</i>)-5-({[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyl-oxy)quinazolin-7-yl]oxy}methyl)hexahydrocyclopenta[<i>c</i>]pyrrole-2(1 <i>H</i>)-carboxylate;
<i>N</i> -(3,4-dichloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3 <i>aR</i> ,5 <i>r</i> ,6 <i>aS</i>)-octahydrocyclopenta[<i>c</i>]pyrrol-5-yl)methyl}oxy}quinazolin-4-amine;
1,1-dimethylethyl (3 <i>aR</i> ,6 <i>aS</i>)-5-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)hexahydrocyclopenta[<i>c</i>]pyrrole-2(1 <i>H</i>)-carboxylate; and
a single geometric isomer , stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

143. **(currently amended)** The Compound of Claim 8485 selected from

<i>N</i> -(3,4-dichloro-2-fluorophenyl)-7-({[(3 <i>aR</i> ,5 <i>r</i> ,6 <i>aS</i>)-2-(1-methylethyl)octahydrocyclopenta[<i>c</i>]pyrrol-5-yl)methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3 <i>aR</i> ,5 <i>r</i> ,6 <i>aS</i>)-2-(1-methylethyl)octahydrocyclopenta[<i>c</i>]pyrrol-5-yl)methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
7-({[(3 <i>aR</i> ,5 <i>r</i> ,6 <i>aS</i>)-2-acetyloctahydrocyclopenta[<i>c</i>]pyrrol-5-yl)methyl}oxy)- <i>N</i> -(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3 <i>aR</i> ,5 <i>r</i> ,6 <i>aS</i>)-octahydrocyclopenta[<i>c</i>]pyrrol-5-yl)methyl}oxy}quinazolin-4-amine;
ethyl (3 <i>aR</i> ,5 <i>r</i> ,6 <i>aS</i>)-5-({[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)hexahydrocyclopenta[<i>c</i>]pyrrole-2(1 <i>H</i>)-carboxylate;
<i>N</i> -(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3 <i>aR</i> ,5 <i>r</i> ,6 <i>aS</i>)-2-(methylsulfonyl)octahydrocyclopenta[<i>c</i>]pyrrol-5-yl)methyl}oxy)quinazolin-4-amine;

<i>N</i> -(3,4-dichloro-2-fluorophenyl)-7-({[(3 <i>R</i> ,5 <i>r</i> ,6 <i>aS</i>)-2-ethyloctahydrocyclopenta[<i>c</i>]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(3,4-dichloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3 <i>R</i> ,5 <i>r</i> ,6 <i>aS</i>)-2-(2-methylpropyl)octahydrocyclopenta[<i>c</i>]pyrrol-5-yl]methyl}oxy)quinazolin-4-amine;
<i>N</i> -(3,4-dichloro-2-fluorophenyl)-7-({[(3 <i>R</i> ,5 <i>s</i> ,6 <i>aS</i>)-2-methyloctahydrocyclopenta[<i>c</i>]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(3,4-dichloro-2-fluorophenyl)-7-({[(3 <i>R</i> ,5 <i>r</i> ,6 <i>aS</i>)-2-methyloctahydrocyclopenta[<i>c</i>]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3 <i>R</i> ,5 <i>r</i> ,6 <i>aS</i>)-2-methyloctahydrocyclopenta[<i>c</i>]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(3-chloro-2,4-difluorophenyl)-7-({[(3 <i>R</i> ,5 <i>r</i> ,6 <i>aS</i>)-2-methyloctahydrocyclopenta[<i>c</i>]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(4,5-dichloro-2-fluorophenyl)-7-({[(3 <i>R</i> ,5 <i>r</i> ,6 <i>aS</i>)-2-methyloctahydrocyclopenta[<i>c</i>]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(4-bromo-5-chloro-2-fluorophenyl)-7-({[(3 <i>R</i> ,5 <i>r</i> ,6 <i>aS</i>)-2-methyloctahydrocyclopenta[<i>c</i>]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(4-bromo-2,3-dichlorophenyl)-7-({[(3 <i>R</i> ,5 <i>r</i> ,6 <i>aS</i>)-2-methyloctahydrocyclopenta[<i>c</i>]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(3,4-dichlorophenyl)-7-({[(3 <i>R</i> ,5 <i>r</i> ,6 <i>aS</i>)-2-methyloctahydrocyclopenta[<i>c</i>]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3 <i>R</i> ,5 <i>r</i> ,6 <i>aS</i>)-2-ethyloctahydrocyclopenta[<i>c</i>]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3 <i>R</i> ,5 <i>r</i> ,6 <i>aS</i>)-2-(2-methylpropyl)octahydrocyclopenta[<i>c</i>]pyrrol-5-yl]methyl}oxy)quinazolin-4-amine; and
1,1-dimethylethyl (3 <i>aR</i> ,6 <i>aS</i>)-5-({[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyl-oxy)quinazolin-7-yl]oxy}methyl)hexahydrocyclopenta[<i>c</i>]pyrrole-2(1 <i>H</i>)-carboxylate;
<i>N</i> -(3,4-dichloro-2-fluorophenyl)-6-(methyloxy)-7-{{[(3 <i>aR</i> ,5 <i>r</i> ,6 <i>aS</i>)-octahydrocyclopenta[<i>c</i>]pyrrol-5-yl]methyl}oxy}quinazolin-4-amine
1,1-dimethylethyl (3 <i>aR</i> ,6 <i>aS</i>)-5-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl) hexahydrocyclopenta-[<i>c</i>]pyrrole-2(1 <i>H</i>)-carboxylate; and
a single geometrie isomer , stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

144. **(currently amended)** The Compound of Claim 143 selected from *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3*aR*,5*r*,6*aS*)-2-methyloctahydrocyclopenta[*c*]pyrrol-5-yl)methyl}oxy)-6-(methyloxy)quinazolin-4-amine; *N*-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3*aR*,5*r*,6*aS*)-2-methyloctahydrocyclopenta[*c*]pyrrol-5-yl)methyl}oxy)-6-(methyloxy)quinazolin-4-amine; and *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3*aR*,5*s*,6*aS*)-2-methyloctahydrocyclopenta[*c*]pyrrol-5-yl)methyl}oxy)-6-(methyloxy)quinazolin-4-amine; and optionally as a pharmaceutically acceptable salt or hydrate thereof.

145. **(previously presented)** The pharmaceutical composition of Claim 144.

146. **(currently amended)** The Compound of Claim 143 selected from 1,1-dimethylethyl (3*aR*,6*aS*)-5-({[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)hexahydrocyclopenta[*c*]pyrrole-2(1*H*)-carboxylate; *N*-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3*aR*,5*r*,6*aS*)-octahydrocyclopenta[*c*]pyrrol-5-yl)methyl}oxy}quinazolin-4-amine; *N*-(3,4-dichloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3*aR*,5*r*,6*aS*)-octahydrocyclopenta[*c*]pyrrol-5-yl)methyl]oxy}quinazolin-4-amine; 1,1-dimethylethyl (3*aR*,6*aS*)-5-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl) hexahydrocyclopenta[*c*]pyrrole-2(1*H*)-carboxylate; and a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

147. **(currently amended)** The Compound of Claim 144 named *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3*aR*,5*r*,6*aS*)-2-methyloctahydrocyclopenta[*c*]pyrrol-5-yl)methyl}oxy)-6-(methyloxy)quinazolin-4-amine optionally as a pharmaceutically acceptable salt or hydrate thereof.

148. **(previously presented)** The pharmaceutical composition of Claim 147.

149. **(currently amended)** The Compound of Claim 96 selected from

(3*S*,9*aS*)-3-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)hexahydro-2*H*-pyrido[1,2-*a*]pyrazin-1(6*H*)-one;

(3 <i>S</i> ,9 <i>aR</i>)-3-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)hexahydro-2 <i>H</i> -pyrido[1,2- <i>a</i>]pyrazin-1(6 <i>H</i>)-one;
(3 <i>S</i> ,8 <i>aS</i>)-3-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)hexahydropyrrolo[1,2- <i>a</i>]pyrazin-1(2 <i>H</i>)-one;
(3 <i>S</i> ,8 <i>aR</i>)-3-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)hexahydropyrrolo[1,2- <i>a</i>]pyrazin-1(2 <i>H</i>)-one;
(3 <i>S</i> ,8 <i>aS</i>)-3-({[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)hexahydropyrrolo[1,2- <i>a</i>]pyrazin-1(2 <i>H</i>)-one;
(3 <i>S</i> ,8 <i>aS</i>)-3-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-2-methylhexahydropyrrolo[1,2- <i>a</i>]pyrazin-1(2 <i>H</i>)-one; and
a single geometric isomer , stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

150. (currently amended) The Compound of Claim 99 selected from

<i>N</i>-(3,4-dichlorophenyl)-7-({2-[(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)amino]ethyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i>-(3,4-dichlorophenyl)-7-({2-[(3-<i>endo</i>)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]amino}ethyl)oxy}-6-(methyloxy)quinazolin-4-amine;
<i>N</i>-(3,4-dichlorophenyl)-7-{{2-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)ethyl}oxy}-6-(methyloxy)quinazolin-4-amine;
<i>N</i>-(3,4-dichlorophenyl)-7-({2-[(3-<i>endo</i>)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]ethyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i>-(3,4-dichlorophenyl)-7-{{[(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine;
<i>N</i>-(3,4-dichlorophenyl)-7-({[(3-<i>endo</i>)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i>-(3,4-dichlorophenyl)-7-{{8-methyl-8-azabicyclo[3.2.1]oct-3-yl}oxy}-6-(methyloxy)quinazolin-4-amine;
<i>N</i>-(3,4-dichlorophenyl)-7-{{[(3-<i>exo</i>)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]oxy}-6-(methyloxy)quinazolin-4-amine;
7-{{[(3-<i>endo</i>)-8-azabicyclo[3.2.1]oct-3-ylmethyl]oxy}-<i>N</i>-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine;

1,1-dimethylethyl (3-endo)-3-(2-([4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy)ethyl)-8-azabicyclo[3.2.1]octane-8-carboxylate; and
7-((2-[(3-endo)-8-azabicyclo[3.2.1]oct-3-yl]ethyl)oxy)-N-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine; and
a single geometric isomer , stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

151. (canceled)

152. (currently amended) The Compound of Claim 120 selected from

1,4:3,6-dianhydro-5-([4-[(4-bromo-5-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy)methyl)-5-deoxy-2-O-methyl-D-xylo-hexitol;
1,4:3,6-dianhydro-5-deoxy-5-([4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy)methyl)-2-O-methyl-D-glucitol;
1,4:3,6-dianhydro-5-deoxy-5-([4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy)methyl)-2-O-methyl-D-xylo-hexitol;
1,4:3,6-dianhydro-5-([4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy)methyl)-5-deoxy-2-O-methyl-D-xylo-hexitol;
1,4:3,6-dianhydro-5-([4-[(3-chloro-2,4-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy)methyl)-5-deoxy-2-O-methyl-D-xylo-hexitol;
1,4:3,6-dianhydro-5-([4-[(4-bromo-2,3-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy)methyl)-5-deoxy-2-O-methyl-D-glucitol;
1,4:3,6-dianhydro-2-deoxy-2-([4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy)methyl)-5-O-methyl-D-threo-hexitol;
1,4:3,6-dianhydro-5-deoxy-5-([4-[(4,5-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy)methyl)-2-O-methyl-D-glucitol;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-5-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol;
1,4:3,6-dianhydro-2-O-[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol;
1,4:3,6-dianhydro-2-O-methyl-5-O-{6-(methyloxy)-4-[(2,3,4-trichlorophenyl)amino]quinazolin-7-yl}-L-iditol;

1,4:3,6-dianhydro-5-O-[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-O-methyl-D-xylitol;
1,4:3,6-dianhydro-5-O-[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-O-methyl-D-glucitol;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-2,3-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-L-sorbose-ethylene-glycol-acetal;
1,4:3,6-dianhydro-2-O-[4-[(3-chloro-2,4-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol;
1,4:3,6-dianhydro-2-O-[4-[(4,5-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-(difluoromethyl)-L-iditol;
1,4:3,6-dianhydro-2-O-[4-[(3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol;
1,4:3,6-dianhydro-2-O-[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-ethyl-L-iditol;
1,4:3,6-dianhydro-2-O-[4-[(3-bromo-2-methylphenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol;
1,4:3,6-dianhydro-2-O-[4-[(3-chloro-2-methylphenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-deoxy-D-xylitol;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-D-glucitol;
methyl 3,6-anhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-O-methyl-alpha-L-ideofuranoside;

1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-deoxy-5-methylidene-D-xyllo-hexitol;
methyl 3,6-anhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-O-methyl-beta-L-idofuranoside;
1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-O-[6-(methyloxy)-4-[(2,3,4-trifluorophenyl)amino]quinazolin-7-yl]-D-iditol;
1,4:3,6-dianhydro-5-O-[4-[(2-chloro-4-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-O-[4-[(2-bromo-4-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-2-deoxy-5-O-[4-[(2,6-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-O-[4-[(3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-O-[4-[[4-fluoro-3-(trifluoromethyl)phenyl]amino]-6-(methyloxy)quinazolin-7-yl]-D-iditol;
1,4:3,6-dianhydro-2-deoxy-5-O-[4-[(2,4-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol;
1,4:3,6-dianhydro-2-deoxy-5-O-[4-[(2,5-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol;
1,4:3,6-dianhydro-2-deoxy-5-O-[4-[(2,3-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-O-[4-[(5-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-2-deoxy-5-O-[4-[(3,5-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-O-[4-[(3-chloro-4-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-2-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-2-deoxy-5-O-[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol;

1,4:3,6-dianhydro-5-O-[4-[(4-bromo-5-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-itol;
1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-O-[6-(methyloxy)-4-[(2,4,5-trifluorophenyl)amino]quinazolin-7-yl]-D-itol;
1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-O-[6-(methyloxy)-4-[(2,4,6-trifluorophenyl)amino]quinazolin-7-yl]-D-itol;
1,4:3,6-dianhydro-5-O-[4-[(4-[(4-chlorophenyl)oxy]-3,5-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-itol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-itol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-2,3-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-itol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chloro-5-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-itol;
1,4:3,6-dianhydro-2-deoxy-5-O-[4-[(4,5-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-itol;
1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-O-[6-(methyloxy)-4-[(2,3,4-trichlorophenyl)amino]quinazolin-7-yl]-D-itol;
1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-O-[6-(methyloxy)-4-[(3,4,5-trichlorophenyl)amino]quinazolin-7-yl]-D-itol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-itol;
1,4:3,6-dianhydro-5-O-[4-[(4-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-itol;
1,4:3,6-dianhydro-5-O-[4-[(3-chloro-2-methylphenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-itol;
1,4:3,6-dianhydro-2-deoxy-5-O-[4-[(3,4-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-itol;
1,4:3,6-dianhydro-2-deoxy-5-O-[4-[(2,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-itol;
1,4:3,6-dianhydro-2-deoxy-5-O-[4-[(2,5-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-itol;

1,4:3,6-dianhydro-2-deoxy-5-O-[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-itol;
1,4:3,6-dianhydro-5-O-[4-[(2-bromo-4,6-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-itol;
1,4:3,6-dianhydro-5-O-[4-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-itol;
1,4:3,6-dianhydro-5-O-[4-[[2-chloro-5-(trifluoromethyl)phenyl]amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-itol;
1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-O-[4-[[2-fluoro-3-(trifluoromethyl)phenyl]amino]-6-(methyloxy)quinazolin-7-yl]-D-itol;
1,4:3,6-dianhydro-5-O-[4-[[2-bromo-5-(trifluoromethyl)phenyl]amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-itol;
1,4:3,6-dianhydro-5-O-[4-[[2-bromo-4-(trifluoromethyl)phenyl]amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-itol;
1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-O-[4-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-6-(methyloxy)quinazolin-7-yl]-D-itol;
1,4:3,6-dianhydro-5-O-[4-[[3-bromo-5-(trifluoromethyl)phenyl]amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-itol;
1,4:3,6-dianhydro-5-O-[4-[(3-bromo-4-methylphenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-itol;
1,4:3,6-dianhydro-5-O-[4-[(5-chloro-2-methylphenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-itol;
1,4:3,6-dianhydro-2-deoxy-5-O-[4-[(3,5-dimethylphenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-itol;
1,4:3,6-dianhydro-5-O-[4-[[2,5-bis(methyloxy)phenyl]amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-itol;
1,4:3,6-dianhydro-5-O-[4-[[5-chloro-2,4-bis(methyloxy)phenyl]amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-itol;
1,4:3,6-dianhydro-5-O-[4-[[4-chloro-2,5-bis(methyloxy)phenyl]amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-itol;
1,4:3,6-dianhydro-5-O-[4-[(3-chloro-2,4-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-itol;

1,4:3,6 dianhydro 5-O [4 [(3-chloro 2-fluorophenyl)amino] 6-(methyloxy)quinazolin-7-yl] 2-deoxy-2-fluoro-L-iditol;
1,4:3,6 dianhydro 2-O [4 [(4-bromo 3-chlorophenyl)amino] 6-(methyloxy)quinazolin-7-yl] 5-O-methyl 5-C [(methyloxy)methyl] L-glucitol;
1,4:3,6 dianhydro 5-O [4 [(4-bromo 3-chlorophenyl)amino] 6-(methyloxy)quinazolin-7-yl] 2-O-methyl 2-C [(methyloxy)methyl] D-iditol;
1,4:3,6 dianhydro 2-O [4 [(4-bromo 3-chlorophenyl)amino] 6-(methyloxy)quinazolin-7-yl] L-glucitol;
1,4:3,6 dianhydro 2-O [4 [(4-bromo 3-chlorophenyl)amino] 6-(methyloxy)quinazolin-7-yl] D-glucitol;
1,4:3,6 dianhydro 2-O [4 [(4-bromo 3-chlorophenyl)amino] 6-(methyloxy)quinazolin-7-yl] 5-S-methyl 5-thio-D-iditol;
1,4:3,6 dianhydro 2-O [4 [(4-bromo 3-chlorophenyl)amino] 6-(methyloxy)quinazolin-7-yl] 5-S-methyl 5-thio-L-iditol;
1,4:3,6 dianhydro 5-O [4 [(4-bromo 3-chlorophenyl)amino] 6-(methyloxy)quinazolin-7-yl] 2-deoxy-2-morpholin-4-yl-D-iditol;
1,4:3,6 dianhydro 5-O [4 [(4-bromo 3-chlorophenyl)amino] 6-(methyloxy)quinazolin-7-yl] 2-deoxy-2-morpholin-4-yl-L-iditol;
1,4:3,6 dianhydro 5-O [4 [(4-bromo 3-chlorophenyl)amino] 6-(methyloxy)quinazolin-7-yl] 2-deoxy-2-(4-methylpiperazin-1-yl)-D-iditol;
1,4:3,6 dianhydro 5-O [4 [(4-bromo 3-chlorophenyl)amino] 6-(methyloxy)quinazolin-7-yl] 2-deoxy-2-(4-methylpiperazin-1-yl)-L-iditol;
1,4:3,6 dianhydro 5-O [4 [(4-bromo 3-chlorophenyl)amino] 6-(methyloxy)quinazolin-7-yl] 2-deoxy-2-pyrrolidin-1-yl-D-iditol;
1,4:3,6 dianhydro 5-O [4 [(4-bromo 3-chlorophenyl)amino] 6-(methyloxy)quinazolin-7-yl] 2-deoxy-2-pyrrolidin-1-yl-L-iditol;
2-O-acetyl 1,4:3,6 dianhydro 5-O [4 [(4-bromo 3-chlorophenyl)amino] 6-(methyloxy)quinazolin-7-yl] D-iditol;
2-O-acetyl 1,4:3,6 dianhydro 5-O [4 [(4-bromo 3-chlorophenyl)amino] 6-(methyloxy)quinazolin-7-yl] L-iditol;
1,4:3,6 dianhydro 2-O [4 [(4-bromo 3-chlorophenyl)amino] 6-(methyloxy)quinazolin-7-yl] D-iditol;

1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-L-iditol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-(methylsulfonyl)-D-iditol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-(methylsulfonyl)-L-iditol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-(dimethylamino)-D-iditol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-(dimethylamino)-L-iditol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-(diethylamino)-D-iditol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-(diethylamino)-L-iditol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-piperidin-1-yl-D-iditol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-piperidin-1-yl-L-iditol;
2-(acetylamino)-1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-D-iditol;
2-(acetylamino)-1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-L-iditol;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-5-C-(trifluoromethyl)-L-glucitol;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-5-C-(trifluoromethyl)-D-glucitol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-[(methylsulfonyl)amino]-D-iditol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-[(methylsulfonyl)amino]-L-iditol;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-C-(trifluoromethyl)-D-glucitol;

a single ~~geometric isomer~~, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt ~~or hydrate~~ thereof.

153. **(canceled)**

154. **(canceled)**

155. **(new)** A pharmaceutical composition comprising a compound of Formula I as defined in any one of Claims 67, 79, 84, 89, 96, 99, 138, 139, 140, 141, 142, 143, 146, and 150 or Ia as defined in any one of Claims 113, 114, and 152 and a pharmaceutically acceptable carrier.